{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:32:39Z","timestamp":1793338359485,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.amjcard.2020.03.043","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T01:56:44Z","timestamp":1586224604000},"page":"94-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations"],"prefix":"10.1016","volume":"126","author":[{"given":"Nishant P.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha J.","family":"Pajidipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-7152","authenticated-orcid":false,"given":"Robert W.","family":"McGarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreekanth","family":"Vemulapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Blazing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svati H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-9616","authenticated-orcid":false,"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.03.043_bib0001","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacl.2017.06.015","article-title":"Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis","volume":"11","author":"Wong","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0002","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1053\/euhj.1998.1043","article-title":"Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes","volume":"19","author":"Stubbs","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0003","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0004","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0006","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0007","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a)","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0008","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0009","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.gr.2012.11.009","article-title":"Mantle sources and magma evolution beneath the Cameroon Volcanic Line: geochemistry of mafic rocks from the Bamenda Mountains (NW Cameroon)","volume":"24","author":"Kamgang","year":"2013","journal-title":"Gondwana Res"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0011","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0022-2275(20)32100-3","article-title":"Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard","volume":"40","author":"Kostner","year":"1999","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0012","article-title":"Exchange-driven magnetoresistance in silicon facilitated by electrical spin injection","author":"Ando","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0013","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1161\/ATVBAHA.108.179697","article-title":"Oxidized low-density lipoprotein and atherosclerosis","volume":"30","author":"Steinberg","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0014","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0016","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0018","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/00005768-199711000-00007","article-title":"Effects of physical activity and diet on lipoprotein(a)","volume":"29","author":"Mackinnon","year":"1997","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0019","article-title":"Effect of dietary modification by calorie restriction on cholesterol levels in lipoprotein(a) and other lipoprotein classes","author":"Hirowatari","year":"2016","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0020","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.2480","article-title":"Large-scale association analysis identifies new risk loci for coronary artery disease","volume":"45","author":"Deloukas","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0022","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0023","first-page":"203","article-title":"Causal effect of lipids and lipoproteins on atherosclerosis","volume":"36","author":"Ference","year":"2018","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0024","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Tipping","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0025","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.amjcard.2020.03.043_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007372","article-title":"Associations of lipoprotein(a) levels with incident atrial fibrillation and ischemic stroke: the ARIC (Atherosclerosis Risk in Communities) study","volume":"6","author":"Aronis","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.amjcard.2020.03.043_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005967","article-title":"Twenty\u2010year predictors of peripheral arterial disease compared with coronary heart disease in the Scottish Heart Health Extended Cohort (SHHEC)","volume":"6","author":"Tunstall\u2010Pedoe","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2017.06.015","article-title":"Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis","author":"Wong","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0029","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a)","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0030","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.atherosclerosis.2011.02.007","article-title":"Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia","volume":"216","author":"Nenseter","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0031","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0032","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0033","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0034","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-007-0585-z","article-title":"Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia","author":"Meri\u00f1o-Ibarra","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2019.06.011","article-title":"Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels","author":"Pavanello","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0036","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11883-015-0502-0","article-title":"Targeting lipoprotein (a): an evolving therapeutic landscape","volume":"17","author":"Man","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0037","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/0003319719854872","article-title":"Lipoprotein (a) and 10-year cardiovascular disease incidence in apparently healthy individuals: a sex-based sensitivity analysis from ATTICA cohort study","volume":"70","author":"Kouvari","year":"2019","journal-title":"Angiology"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0038","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a Mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0039","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.atherosclerosis.2017.05.014","article-title":"The association of lipoprotein(a) with incident heart failure hospitalization: atherosclerosis risk in communities study","volume":"262","author":"Agarwala","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and cardiovascular risk prediction among women","volume":"72","author":"Cook","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0041","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/eurheartj\/ehy334","article-title":"Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting","volume":"39","author":"Verbeek","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0042","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0043","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0044","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0045","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0046","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0047","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of alirocumab on lipoprotein(a) Over \u22651.5 years (from the Phase 3 ODYSSEY Program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0048","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2018.07.001","article-title":"Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease","volume":"276","author":"Sanchez Mu\u00f1oz-Torrero","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0050","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1194\/jlr.C085639","article-title":"In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes","volume":"59","author":"Tsimikas","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0051","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1194\/jlr.P082792","article-title":"LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk","volume":"59","author":"Mu-Han-Ha-Li","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0052","doi-asserted-by":"crossref","DOI":"10.2337\/dc19-0274","article-title":"Lipoprotein(a) and cardiovascular outcomes in coronary artery disease patients with prediabetes and diabetes","author":"Jin","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0053","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0054","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels secondary analysis of a randomized clinical trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0055","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0056","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0057","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0058","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0059","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/clc.23027","article-title":"Consumption of a defined, plant-based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks","volume":"41","author":"Najjar","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0060","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0061","first-page":"1","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"1","author":"Tsimikas","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0062","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.283.14.1845","article-title":"Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause","volume":"283","author":"Shlipak","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0063","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0064","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","volume":"10","author":"Duell","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0065","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145)","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0066","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0067","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0068","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0069","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.03.043_bib0071","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920303325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920303325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:34:04Z","timestamp":1757572444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914920303325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":71,"alternative-id":["S0002914920303325"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.03.043","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.03.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}